Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OmniAb (OABI) Cash & Equivalents: 2021-2025

Historic Cash & Equivalents for OmniAb (OABI) over the last 4 years, with Sep 2025 value amounting to $28.5 million.

  • OmniAb's Cash & Equivalents rose 4.78% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year increase of 4.78%. This contributed to the annual value of $27.6 million for FY2024, which is 68.71% up from last year.
  • According to the latest figures from Q3 2025, OmniAb's Cash & Equivalents is $28.5 million, which was up 56.10% from $18.3 million recorded in Q2 2025.
  • In the past 5 years, OmniAb's Cash & Equivalents registered a high of $33.4 million during Q4 2022, and its lowest value of $19,847 during Q3 2022.
  • Its 3-year average for Cash & Equivalents is $21.3 million, with a median of $21.0 million in 2023.
  • Per our database at Business Quant, OmniAb's Cash & Equivalents tumbled by 94.52% in 2022 and then skyrocketed by 106,943.89% in 2023.
  • Quarterly analysis of 5 years shows OmniAb's Cash & Equivalents stood at $362,203 in 2021, then slumped by 94.52% to $33.4 million in 2022, then plummeted by 51.01% to $16.4 million in 2023, then soared by 68.71% to $27.6 million in 2024, then rose by 4.78% to $28.5 million in 2025.
  • Its Cash & Equivalents was $28.5 million in Q3 2025, compared to $18.3 million in Q2 2025 and $10.9 million in Q1 2025.